IL7R and neoplasm: By supplementing IL-7 during the in vitro expansion of CAR-T cells (51), constructing CAR-T cells that express IL-7 or IL-7R (36, 52), or treating mice with modified IL-7 following CAR-T infusion (53, 54), the persistence and anti-tumor efficacy of CAR-T cells can be significantly enhanced.